Airtel consolidates its position to defend against Reliance Jio businesstoday.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesstoday.in Daily Mail and Mail on Sunday newspapers.
Bharti Airtel share falls over 2% post Q4 earnings
Share of Bharti Airtel touched an intraday low of Rs 537.1, losing 2.27% on BSE. The stock has lost 6.15% in the last 5 days
BusinessToday.In | May 18, 2021 | Updated 14:09 IST
Airtel share trades higher than 50 day and 200 day moving averages but lower than 5 day, 20 day and 100 day moving averages.
Bharti Airtel share fell over 2% today after the telco reported a consolidated net profit of Rs 759 crore for the fourth quarter ended March 31, 2021. The firm has reported a loss of Rs 5,237 crore in the same period a year ago.
Share of Bharti Airtel touched an intraday low of Rs 537.1, losing 2.27% on BSE. The stock has lost 6.15% in the last 5 days. Airtel share trades higher than 50 day and 200 day moving averages but lower than 5 day, 20 day and 100 day moving averages. The large cap share has lost 0.22% in one year but risen 5.43% since the beginning of this year.
: Wednesday, May 19, 2021, 12:26 AM IST
Stocks to watch: Axis Bank, Panacea Biotec, Torrent Pharma, Ujjivan SFB, Abbott India, L&T, Canara Bank, Tata Motors others
There are some stocks that may be much more active than others. So, some stocks to watch out for today are:
Axis Bank: Specified Undertaking of the Unit Trust of India (SUUTI) is looking at selling 3.6 crore shares via offer for sale (OFS) in private lender Axis Bank at a floor price of Rs 680 per share. This will help the government raise up to Rs 3,949.34 crore.
Panacea Biotec: Although Serum Institute of India (SII) CEO Adar Poonawalla on Monday offloaded his entire stake in Panacea Biotec amounting to 5.15 per cent shareholding of the firm, SII continues to hold 9.83 per cent stake in Panacea Biotec. The listed company informed the exchange that Poonawallaâs company SII through various holding and investing companies has a 9.83 per cent stake in Panacea Biotec.